ジソピラミド
参考資料

↑  Guyton, Arthur C.; Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders
↑  Rizos, I; Brachmann, J; Lengfelder, W; Schmitt, C; von Olshausen, K; Kübler, W; Senges, J (1987). “Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: Intraindividual comparison in patients with sustained ventricular tachycardia”. European Heart Journal 8 (2):  154–63. doi:10.1093/oxfordjournals.eurheartj.a062243. PMID 3569310.
1 2 3  Kim, S. Y.; Benowitz, N. L. (1990). “Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide”. Drug Safety 5 (6):  393–420. doi:10.2165/00002018-199005060-00002. PMID 2285495.
1 2  Levites, R; Anderson, G. J. (1979). “Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia”. American Heart Journal 98 (3):  339–44. doi:10.1016/0002-8703(79)90046-2. PMID 474380.
1 2 3 4 5  Mathur, P. P. (1972). “Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate”. American Heart Journal 84 (6):  764–70. doi:10.1016/0002-8703(72)90069-5. PMID 4150336.
1 2  “リスモダンP静注50mg 添付文書”. www.info.pmda.go.jp. 2022年1月11日閲覧。
1 2  “リスモダンR錠150mg 添付文書”. www.info.pmda.go.jp. 2022年1月11日閲覧。
1 2  “リスモダンカプセル100mg／リスモダンカプセル50mg 添付文書”. www.info.pmda.go.jp. 2022年1月11日閲覧。
↑  Rang and Dale's pharmacology
↑  Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199:41-51, 1976.
↑  Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders.
↑  Katzung, Bertram G., Masters, Susan B., Trevor, Anthony J. (2009). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill
↑  “肥大型心筋症（指定難病５８） – 難病情報センター”. www.nanbyou.or.jp. 2022年1月12日閲覧。
1 2  “Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment”. J Am Coll Cardiol 58:  2313–2321. (2011). doi:10.1016/j.jacc.2011.08.040.
1 2  “Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy”. J Am Coll Cardiol 45 (8):  1251–1258. (2005). doi:10.1016/j.jacc.2005.01.012. PMID 15837258.
↑  “Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy”. Heart 92 (6):  785–791. (2006). doi:10.1136/hrt.2005.068577. PMC 1860645. PMID 16216855. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645/.
1 2 3 4 5  Sherrid, M. V.; Shetty, A; Winson, G; Kim, B; Musat, D; Alviar, C. L.; Homel, P; Balaram, S. K. et al. (2013). “Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil”. Circulation: Heart Failure 6 (4):  694–702. doi:10.1161/CIRCHEARTFAILURE.112.000122. PMID 23704138.
↑  Pollick C (1982). “Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide”. N Engl J Med 307 (16):  997–999. doi:10.1056/nejm198210143071607.
↑  “accf/aha guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. J Am Coll Cardiol 58 (25):  e212–260. (2011). doi:10.1016/j.jacc.2011.06.011. PMID 22075469.
↑  Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-1312
↑  “Disopyramide-pyridostigmine interaction: Selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect”. J Am Coll Cardiol 10 (3):  633–641. (1987). doi:10.1016/s0735-1097(87)80207-3.
↑  Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:483-492